Table 1 Demographic and clinical characteristics at baseline of refractory chronic migraine patients treated with Erenumab
From: A prospective real-world analysis of erenumab in refractory chronic migraine
Total number of patients | |
|---|---|
Sex, M/F | 27/135 |
Age (y), mean ± SD | 46 ± 14.3 |
CM duration (y), mean ± SD | 13 ± 11.9 |
Aura, N (%) | 53 (33%) |
Medication overuse, N (%) | 87 (54%) |
Mean ± St. Error | |
Migraine days | 19.7 ± 0.7 |
Headache days | 23.4 ± 0.6 |
Headache free days | 3.7 ± 0.4 |
Abortive treatment intake days | 11.5 ± 0.7 |
HIT-6 score | 67.6 ± 0.4 |
Number of preventive treatments failed | 8.4 ± 3.6 |
BoNT/A non-responders | 148 (91.4%) |